Skip to main content
Premium Trial:

Request an Annual Quote

Euformatics Receives CE Mark for OmnomicsNGS Clinical Decision Support Tool

NEW YORK (GenomeWeb) – Finnish bioinformatics firm Euformatics announced today that it has received CE Marking for omnomicsNGS, a tool that helps labs interpret genetic variants and make clinical decisions.

The tool can help determine whether individual variants can have an effect on a patient's disease risk, or response to drugs or treatment, the company said. It performs variant annotation using the most recent disease-specific translational research and user-provided knowledge.

Euformatics launched the omnomicsQ, a management system for NGS workflows, in April 2015. The system lets users lay out quality metrics, draw up plans that determine the standards that are needed for NGS projects, and define tests that determine if a project conforms to the quality specifications laid out in the quality management plan. It's also the only quality management software that allows diagnostic laboratories to follow CAP or EuroGentest guidelines, the company said.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.